Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2011 4
2012 2
2013 5
2014 6
2015 6
2016 8
2017 6
2018 2
2019 8
2020 28
2021 17
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Results by year
Filters applied: . Clear all
Page 1
Neuroimmune cardiovascular interfaces control atherosclerosis.
Mohanta SK, Peng L, Li Y, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed BR, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, Klupp BG, Megens RTA, Steffens S, Pelisek J, Eckstein HH, Kleemann R, Habenicht L, Mallat Z, Michel JB, Bernhagen J, Dichgans M, D'Agostino G, Guzik TJ, Olofsson PS, Yin C, Weber C, Lembo G, Carnevale D, Habenicht AJR. Mohanta SK, et al. Among authors: hu d. Nature. 2022 May;605(7908):152-159. doi: 10.1038/s41586-022-04673-6. Epub 2022 Apr 27. Nature. 2022. PMID: 35477759
Diabetes is a risk factor for the progression and prognosis of COVID-19.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Guo W, et al. Among authors: hu d. Diabetes Metab Res Rev. 2020 Mar 31;36(7):e3319. doi: 10.1002/dmrr.3319. Online ahead of print. Diabetes Metab Res Rev. 2020. PMID: 32233013 Free PMC article.
ApoE attenuates unresolvable inflammation by complex formation with activated C1q.
Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR. Yin C, et al. Among authors: hu d. Nat Med. 2019 Mar;25(3):496-506. doi: 10.1038/s41591-018-0336-8. Epub 2019 Jan 28. Nat Med. 2019. PMID: 30692699 Free PMC article.
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.
Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, Du XJ, Fang WF, Feng M, Gao J, Han F, He X, Hu CS, Hu DS, Hu GY, Jiang H, Jiang W, Jin F, Lang JY, Li JG, Lin SJ, Liu X, Liu QF, Ma L, Mai HQ, Qin JY, Shen LF, Sun Y, Wang PG, Wang RS, Wang RZ, Wang XS, Wang Y, Wu H, Xia YF, Xiao SW, Yang KY, Yi JL, Zhu XD, Ma J. Tang LL, et al. Cancer Commun (Lond). 2021 Nov;41(11):1195-1227. doi: 10.1002/cac2.12218. Epub 2021 Oct 26. Cancer Commun (Lond). 2021. PMID: 34699681 Free PMC article.
Response to editor.
Hu D. Hu D. Transbound Emerg Dis. 2021 Mar;68(2):212. doi: 10.1111/tbed.13829. Epub 2020 Oct 15. Transbound Emerg Dis. 2021. PMID: 32920976 No abstract available.
Roquin Suppresses the PI3K-mTOR Signaling Pathway to Inhibit T Helper Cell Differentiation and Conversion of Treg to Tfr Cells.
Essig K, Hu D, Guimaraes JC, Alterauge D, Edelmann S, Raj T, Kranich J, Behrens G, Heiseke A, Floess S, Klein J, Maiser A, Marschall S, Hrabĕ de Angelis M, Leonhardt H, Calkhoven CF, Noessner E, Brocker T, Huehn J, Krug AB, Zavolan M, Baumjohann D, Heissmeyer V. Essig K, et al. Among authors: hu d. Immunity. 2017 Dec 19;47(6):1067-1082.e12. doi: 10.1016/j.immuni.2017.11.008. Epub 2017 Dec 12. Immunity. 2017. PMID: 29246441 Free article.
Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.
Li M, Guo W, Dong Y, Wang X, Dai D, Liu X, Wu Y, Li M, Zhang W, Zhou H, Zhang Z, Lin L, Kang Z, Yu T, Tian C, Qin R, Gui Y, Jiang F, Fan H, Heissmeyer V, Sarapultsev A, Wang L, Luo S, Hu D. Li M, et al. Among authors: hu d. Front Immunol. 2020 Oct 14;11:580237. doi: 10.3389/fimmu.2020.580237. eCollection 2020. Front Immunol. 2020. PMID: 33154753 Free PMC article.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Among authors: hu d. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
100 results